2025 Q1: Oncology Business Competition Among MNCs
How did MNCs fare in the oncology field during Q1 of this year?
June 4, 2025
by Xiaobin
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
Jan 10, 2025: Menarini Group, its subsidiary Stemline, and Insilico Medicine ink an exclusive license deal. Stemline gets global rights for a pre - clinical oncology small - molecule addressing high unmet needs.
January 10, 2025
by PR Newswire
Has the Booming PD-1 Inhibitor Reached its Limit?
In the field of oncology, Opdivo and Keytruda, as core immunotherapy agents for PD-1 inhibitors, have delivered significant survival benefits to patients with a variety of cancers.
October 18, 2024
by Krebs Qin
Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
October 18, 2024
by Krebs Qin
What To Expect in the 2024 Pharmaceutical Market
The pharmaceutical market is growing fast. According to Statista.The largest market is oncology, predicted to be worth US$214.10 billion in 2024.
January 12, 2024
by Suzanne Elvidge
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting
Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 7, 2022
by PharmaSources.com
A Review of Oncology Biosimilars Products and Companies
Biologics and biosimilars are large and generally complex therapeutics produced from living organisms.
May 12, 2022
by David Orchard-Webb
The Last Ten Shanghai STAR Market Pharmaceutical IPOs
The last ten biopharma companies that have IPO’d on the STAR Market (Shanghai Stock Exchange Science and Technology Innovation Board) are focused on oncology, synthetic biology, genomics, HIV & pain management...
March 16, 2022
by David Orchard-Webb
NASDAQ Biopharma IPOs in the First Half of Q1 2022
So far in the first half of Q1 2022 seven biopharma companies have IPO’d on the NASDAQ.
March 1, 2022
by David Orchard-Webb
Navigo Proteins Appoints Chris-Carol Bremer as Chief Development Officer
Navigo Proteins, a premier protein engineering company developing novel scaffold protein-based affinity ligands called Affilin® molecules from its Precision Targeting Toolbox...
February 7, 2022
by B3Cnewswire
Global Recommendations for Colon Cancer Translated into Multiple Languages as NCCN Expands Arabic Resources
The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—today announced the publication of newly-translated recommendations for treating colon cancer in Arabic...
December 23, 2021
by prnasia
Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company and Foghorn Therapeutics Inc. announced a strategic collaboration to create novel oncology medicines by applying Foghorn's proprietary Gene Traffic Control® platform...
December 14, 2021
by AmericanPharmaceuticalReview